OptimizeRx Corporation

NASDAQ:OPRX

Medical - Healthcare Information Services

Healthcare
$7.31 -0.98%

-$0.05 today

Market cap
$138.21M
Beta
1.10
P/E (TTM)
13.8
EPS (TTM)
$0.36
52W Low $4.57High $22.25

Volume 0.18M

Average 0.47M

OPRX Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

OptimizeRx CorporationNASDAQ: OPRX

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow turns negative

Q1 FY2026 free cash flow was -$488K, compared with $3.84M a year earlier. Trailing-twelve-month free cash flow was $14.33M. Over 3 fiscal years it compounded at +21.5% a year.

Context

  • Free cash flow amounted to 17.0% of revenue in FY2025, up 11.9 pp from a year earlier.
  • Free cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly free cash flow holds near -$488K or moves back toward the trailing-twelve-month quarterly average of $3.58M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$488K-106.9% QoQ
Last fiscal yearDec 2025
$18.66M+290.6% YoY
LTMMar 2026
$14.33M+127.1% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-112.7%——
1 year+290.6%——
3-year CAGR+21.5%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
18.66M USD
Year-over-year change
+290.6%
4-year CAGR
+196.9%

Free Cash Flow vs competitors

How OPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +127.1% is the 4th highest of 10, against a peer median of +16.7%.
  • Free cash flow amounts to 13.4% of revenue for OPRX, versus a peer median of 17.8%.
OPRX Competitors
Free Cash Flow for OPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NAKANakamoto Inc.LTM Mar 2026$45.99M USD+1079.1%+272.9%1173.4%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$45.43M USD-2.6%-21.7%56.0%
TBRGTruBridge, Inc.LTM Mar 2026$41.97M USD+95.1%+39.9%12.1%
DHDefinitive Healthcare Corp.LTM Mar 2026$37.06M USD-22.6%+10.8%15.6%
SPOKSpok Holdings, Inc.LTM Mar 2026$25.53M USD-2.2%+111.1%18.7%
SLPSimulations Plus, Inc.LTM Feb 2026$22.87M USD+130.8%+7.7%28.4%
RXSTRxSight, Inc.LTM Mar 2026$21.58M USD+5.2%-31.9%16.9%
DRUGBright Minds Biosciences Inc.LTM Mar 2026CA$20.08M CAD+384.8%-13.8%—
NRCNational Research CorporationLTM Mar 2026$17.43M USD+16.7%-15.9%12.6%
OPRXOptimizeRx CorporationLTM Mar 2026$14.33M USD+127.1%+21.5%13.4%
Peer median (excluding OPRX) —+16.7%+7.7%17.8%

Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income378.08K(11.44M)(17.57M)(20.11M)5.13M
Depreciation & Amortization1.97M2.02M2.4M4.33M4.33M
Deferred Income Tax0001.45M1.21M
Stock-Based Compensation5.49M15.75M13.72M11.47M6.96M
Change in Working Capital(7.19M)3.96M(15.55M)921K816K
Accounts Receivables(6.99M)2.28M(8.71M)(2.17M)460K
Inventory00000
Accounts Payables(603.09K)555.4K195K(72K)(520K)
Other Working Capital408.65K1.12M(7.03M)3.16M876K
Other Non-Cash Items80K363.51K9.76M6.83M264K
Operating Cash Flow726.04K10.65M(7.24M)4.89M18.72M
Capital Expenditures(486K)(244.57K)(871K)(112K)(58K)
Acquisitions (Net)0(2M)(80.41M)00
Purchases of Investments0(55.93M)(162.78M)00
Sales of Investments00218.71M00
Other Investing Activities(385.68K)(163.56K)(774K)(338K)126K
Investing Cash Flow(486K)(58.18M)(25.34M)(450K)68K
Debt Repayment0036.02M(4M)(8M)
Common Stock Issued70.67M000352K
Common Stock Repurchased0(20.02M)(7.52M)(911K)0
Dividends Paid00000
Other Financing Activities3.25M1.07M(278K)0(1.15M)
Financing Cash Flow73.92M(18.95M)28.22M(4.91M)(8.8M)
Effect of Forex Changes00000
Net Change in Cash74.16M(66.47M)(4.36M)(472K)9.99M
Free Cash Flow240.04K10.41M(8.11M)4.78M18.66M

OptimizeRx Corporation

NASDAQ:OPRX

Intrinsic Alpha fair value

Locked

Current Price

$7.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.